AGER and prostate cancer: Taken together, it can be assumed that the RAGE rs1800625 polymorphic variants were associated with higher RAGE expression and tumour aggressiveness in prostate cancer development, leading to perineural invasion and biochemical recurrence in prostate cancer patients yet without grade group upgrade, and ultimately leads to poor prognosis and overall survival rate.